Compugen Ltd.
CGEN
NASDAQ·Healthcare·Biotechnology·Mkt cap $244.9M
$2.59
▲ +1.37%
P/E
6.99
Mkt Cap
$244.9M
52-Wk Range
$1.30–$3.24
52-Week Range
$1.30 - $3.24
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 78.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary checkpoint target discovery platform with novel immune regulators
- Strategic partnerships with pharmaceutical titans (AstraZeneca, BMS, Bayer) validating pipeline
- Diversified immuno-oncology pipeline reducing development risk
- Early-stage myeloid-targeted programs addressing underexplored therapeutic space
Bear Case
1 risk
- High volatility (beta 2.8). Larger-than-normal price swings expected.
Growth
Profitability at risk
Clinical trial progression and potential regulatory approvals of lead candidates
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+23.3% over 3m
Quality
Excellent
Exceptional business - top-tier fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CGEN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 3, 2026
Reported EPS of -$0.07 vs -$0.08 consensus (+12.5% surprise). Revenue of $2.6M vs $1.3M expected (+102.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+12.5%
Revenue trend · last 8Q
—
—
-11%
-81%
-89%
+4477%
-5%
+107%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$17.1M
$1.5M
$2.3M
$1.3M
$1.9M
$67.3M
$2.2M
$2.6M
Margins · last 8Q
Gross
-3.5%
Operating
—
Profit
-269.3%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Leerink · $5.00 · May 21, 2026
vs Industry
How CGEN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related